ATOPIC dermatitis (AD) is the most common chronic inflammatory skin condition, affecting up to 10% of adults and up to 20% of ...

PFIZER, a global biopharmaceutical company, today announced the availability of Cibinqo (abrocitinib) and Staquis (crisaborole) as new additions to the atopic dermatitis treatment spectrum in Malaysia ...

Robert Sidbury MD, MPH, division head of dermatology at Seattle Children’s Hospital and professor in the department of pediatrics at University of Washington School of Medicine, explored the treatment ...

Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a ...

Topical Steroid Withdrawal Diagnostic Criteria Defined by NIH Researchers - Criteria May Help Guide Treatment of Dermatitis ...

Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic ...

A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to ...

Discover a study that investigated how understanding atopic dermatitis endotypes is crucial for advancing personalised ...

Lebrikizumab is comparable or superior to many advanced systemic monotherapies for the short-term treatment of atopic dermatitis.

A medical research team has confirmed that ultrafine bubble showers significantly suppress inflammation in mice with atopic dermatitis due to external factors.

“The results of this study suggest that ultrafine bubble shower treatment might be a new treatment for allergen-induced atopic dermatitis for humans, but this study was conducted on mice and the ...